A Phase 4 interventional study of EXPAREL and Bupivacaine in Pain, sponsored by Pacira Pharmaceuticals, Inc. Completed at 17 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-11.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing Liposomal Bupivacaine in Pain — 5 open to participants now, 5 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain.
Among the 36 studies testing Liposomal Bupivacaine in Pain, this one is the 6th largest by enrollment, is one of 3 that started in 2016, is one of 22 in phase 4, and was the 20th registered.
10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.
Browse Pain studies →5 of the 36 studies testing Liposomal Bupivacaine in Pain are open now, in 2 countries. Recruiting first, the newest first:
Children's Hospital of Orange County · Sites in United States
Ages 7–17 · Healthy volunteers
Jessyka Lighthall · Sites in United States
Ages 18–99 · Healthy volunteers
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Tongliao City People's Hospital · Sites in China
Ages 18–60
By country, each count listing its studies:
Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 22
First in 2013; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 66 across 8,502 interventional studies indexed under Pain.
Median enrollment 60 across the 36 interventional studies. Of the 24 that completed or were terminated, 21 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
29 studies in Pain by Pacira BioSciences, Inc.: none open now, none under way, none of them phase 3. Of 29 finished, 26 (90%) have results posted.
Among the 29 studies in Pain by Pacira BioSciences, Inc., this one is the 8th largest by enrollment, is one of 4 that started in 2016, is one of 6 in phase 4, and was the 20th registered.
Pacira BioSciences, Inc.’s Pain studies by the year they started, since 2007.
4 of the studies testing Liposomal Bupivacaine in Pain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05964868Phase 3Jessyka LighthallEfficacy of Liposomal Bupivacaine Post Septorhinoplasty | 2026-12 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07097493Wake Forest University Health SciencesLiposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty | 2027-06 |
| NCT07795203Tongliao City People's HospitalLiposomal Bupivacaine vs Ropivacaine for Post-hemorrhoidectomy Analgesia | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies testing Liposomal Bupivacaine in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pacira BioSciences, Inc.’s 29 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 4, multicenter, randomized, double-blind, controlled trial in approximately 140 adult subjects undergoing primary unilateral TKA under spinal anesthesia with bupivacaine HCl (10-15 mg).
On Day 0, eligible subjects will be randomized 1:1 to two treatment groups. Subjects in Group 1 will receive local infiltration analgesia (LIA) with EXPAREL 266 mg in 20 mL admixed with bupivacaine hydrochloride (HCl) 0.5% in 20 mL and expanded in volume with 80 mL normal saline (total volume of 120 mL). Subjects in Group 2 will receive LIA with bupivacaine HCl 0.5% in 20 mL expanded in volume with 100 mL normal saline (total volume of 120 mL). Investigators will use their usual surgical technique to perform the TKA.
Study drug will be administered using six 20 cc syringes with 22-gauge needles prior to wound closure. Each stick should deliver approximately 1-1.5 cc to the intended area. The tissue should visibly expand with minimal leakage. Study drug should be injected in the prescribed locations based on the areas of highest nerve density.
Infiltration Technique
Prior to cementation
Syringe #1: Posterior capsule (8-10 sticks medial and 8-10 sticks lateral).
Syringe #2: Femur medial and lateral periosteum, posterior periosteum, suprapatellar/quadriceps tendon (20 sticks).
Syringe #3: Tibia fat pad (5 sticks); pes anserinus, medial collateral ligament, and gutter (15 sticks).
Syringe #4: Circumferential periosteum (15-20 sticks).
After cementation
Syringe #5: Midline quadriceps tendon (10 sticks); retinaculum, medial gutter, femoral to tibia (10 sticks).
Syringe #6: Lateral gutter, femoral to tibial (10 sticks); subcutaneous/closure (10 sticks).
In addition to LIA, all study participants will receive a standardized approach for managing postsurgical pain that includes a scheduled multimodal pain regimen including adjunctive analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), and rescue analgesics as needed.
Postsurgical clinical assessments will include pain intensity scores using a 10-cm visual analog scale (VAS); overall benefit of analgesia score (OBAS) questionnaire; total postsurgical opioid consumption; physical therapy assessment; nurse's satisfaction with overall analgesia; and discharge readiness. Adverse events (AEs) will be recorded from the time the informed consent form is signed through postsurgical Day 29.
Postsurgical health economic outcome assessments will include hospital length of stay (LOS), use of skilled nursing facility, outpatient physical therapy use, hospital readmissions, and use of other health services following discharge (phone calls related to postsurgical pain, unscheduled visits related to postsurgical pain, and visits to emergency department) through postsurgical Day 29.
A follow-up visit will be scheduled for all subjects on postsurgical Day 14. A follow-up phone call will be made on postsurgical Day 29 to all subjects who received study drug to assess for AEs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of EXPAREL 266 mg in 20 mL admixed with bupivacaine HCl 0.5% in 20 mL and expanded in volume with 80 mL normal saline (total volume of 120 mL).
Drug: EXPAREL
Bupivacaine HCl 0.5% in 20 mL expanded in volume with 100 mL normal saline (total volume of 120 mL).
Drug: Bupivacaine
EXPAREL and bupivacaine HCl
Also known as: bupivacaine liposome injectable suspension
Single dose of bupivacaine HCl 0.5%
Also known as: bupivacaine HCl
Area Under The Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores From 12 to 48 Hours
AUC of VAS pain intensity scores from 12 to 48 hours, which represents total pain experienced from 12 to 48 hours. Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, "How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now."
Time frame: From 12-48 hours
Total Postsurgical Opioid Consumption Through 48 Hours
Total postsurgical opioid consumption (converted to oral morphine equivalents) through 48 hours
Time frame: 0-48 hours
Percentage of Opioid-free Subjects at 48 Hours
Time frame: 48 hours
Time to First Opioid Rescue in the First 48 Hours
Time to first opioid rescue was estimated from Kaplan-Meier analysis and presented as quartiles (ie, time to rescue for the first 25% / 50% / 75% of subjects within each treatment group).
Time frame: 48 hours
Overall Benefit of Analgesia Score at 48 Hours
The overall benefit of analgesic score (OBAS) comprises seven questions to assess pain intensity, adverse effects, and patients' satisfaction with analgesia (eg, "Please rate your current pain at rest on a scale between 0=minimal pain and 4=maximum imaginable pain"). Overall scores ranged between 0- 28. OBAS measures patients' benefit from postoperative pain therapy. A lower composite score indicates greater benefit from the therapy.
Time frame: 48 hours
Participants were recruited between April 18, 2016 and February 8, 2017 at 16 sites in the United States
| Milestone | EXPAREL 266 mg + Bupivacaine HCl | Bupivacaine HCl |
|---|---|---|
| Started | 71 | 69 |
| Completed | 68 | 67 |
| Not completed | 3 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Did not receive study drug | 1 | 0 |
| Withdrew: Met exclusion criteria | 0 | 1 |
AUC of VAS pain intensity scores from 12 to 48 hours, which represents total pain experienced from 12 to 48 hours. Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, "How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now."
| cm*hr | EXPAREL | Bupivacaine |
|---|---|---|
| Area Under The Curve (AUC) of Visual Analog Scale (VAS) Pain Intensity Scores From 12 to 48 Hours | 181.523 ± 10.786 | 208.407 ± 10.814 |
Total postsurgical opioid consumption (converted to oral morphine equivalents) through 48 hours
| mg | EXPAREL | Bupivacaine |
|---|---|---|
| Total Postsurgical Opioid Consumption Through 48 Hours | 16.321 ± 6.684 | 80.328 ± 33.249 |
| Participants | EXPAREL | Bupivacaine |
|---|---|---|
| Percentage of Opioid-free Subjects at 48 Hours | 7 | 0 |
Time to first opioid rescue was estimated from Kaplan-Meier analysis and presented as quartiles (ie, time to rescue for the first 25% / 50% / 75% of subjects within each treatment group).
| h | EXPAREL | Bupivacaine |
|---|---|---|
| First quartile | 2.617 (1.083 to 3.233) | 1.00 (0.600 to 1.967) |
| Median quartile | 4.125 (3.333 to 6.133) | 2.917 (2.083 to 3.883) |
| Third quartile | 9.667 (6.250 to 31.083) | 7.200 (4.00 to 12.600) |
The overall benefit of analgesic score (OBAS) comprises seven questions to assess pain intensity, adverse effects, and patients' satisfaction with analgesia (eg, "Please rate your current pain at rest on a scale between 0=minimal pain and 4=maximum imaginable pain"). Overall scores ranged between 0- 28. OBAS measures patients' benefit from postoperative pain therapy. A lower composite score indicates greater benefit from the therapy.
| score on a scale | EXPAREL | Bupivacaine |
|---|---|---|
| Overall Benefit of Analgesia Score at 48 Hours | 4.1 ± 4.08 | 4.6 ± 4.33 |
Collected over From screening to postsurgical day 29. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EXPAREL | 0/70 (0%) | 1/70 (1.4%) | 45/70 (64.3%) |
| Bupivacaine | 0/69 (0%) | 1/69 (1.4%) | 39/69 (56.5%) |
| Event | EXPAREL | Bupivacaine |
|---|---|---|
| InfluenzaInfections and infestations | 0/70 | 1/69 |
| Incision site cellulitisInfections and infestations | 1/70 | 0/69 |
| Event | EXPAREL | Bupivacaine |
|---|---|---|
| NauseaGastrointestinal disorders | 21/70 | 22/69 |
| DizzinessNervous system disorders | 3/70 | 8/69 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 6/70 | 0/69 |
| VomitingGastrointestinal disorders | 5/70 | 5/69 |
| HypokalemiaMetabolism and nutrition disorders | 4/70 | 1/69 |
| AnemiaBlood and lymphatic system disorders | 1/70 | 3/69 |
| ConstipationGastrointestinal disorders | 3/70 | 3/69 |
| Peripheral swellingGeneral disorders | 1/70 | 3/69 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/70 | 3/69 |
| HypotensionVascular disorders | 3/70 | 1/69 |
Safety population included all participants who received study drug, with analysis by actual treatment received.
| Age, Continuous(years) | EXPAREL | Bupivacaine | Total |
|---|---|---|---|
| Mean | 65.7 ± 8.61 | 65.8 ± 7.21 | 65.8 ± 7.92 |
| Sex: Female, Male(Participants) | EXPAREL | Bupivacaine | Total |
|---|---|---|---|
| Female | 43 | 39 | 82 |
| Male | 27 | 30 | 57 |
| Ethnicity (NIH/OMB)(Participants) | EXPAREL | Bupivacaine | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 1 | 5 |
| Not Hispanic or Latino | 66 | 68 | 134 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | EXPAREL | Bupivacaine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 5 | 12 |
| White | 61 | 61 | 122 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | EXPAREL | Bupivacaine | Total |
|---|---|---|---|
| United States | 70 | 69 | 139 |
| Body mass index(kg/m^2) | EXPAREL | Bupivacaine | Total |
|---|---|---|---|
| Mean | 32.395 ± 5.805 | 31.311 ± 5.189 | 31.857 ± 5.515 |
| VAS pain score(cm) | EXPAREL | Bupivacaine | Total |
|---|---|---|---|
| Mean | 1.91 ± 2.120 | 1.89 ± 2.241 | 1.90 ± 2.174 |
| American Association of Anesthesiologists classification(Participants) | EXPAREL | Bupivacaine | Total |
|---|---|---|---|
| 1 | 3 | 2 | 5 |
| 2 | 45 | 40 | 85 |
| 3 | 22 | 27 | 49 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
The record gives a start of Apr 2016, a primary completion of Feb 2017 and a completion of Feb 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2020, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Liposomal Bupivacaine · Bupivacaine